Recursion Pharmaceuticals (RXRX) Projected to Post Earnings on Tuesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is projected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.44) per share and revenue of $19.04 million for the quarter.

Recursion Pharmaceuticals Stock Down 10.3 %

Shares of NASDAQ RXRX opened at $9.28 on Monday. The company has a 50 day simple moving average of $7.56 and a 200 day simple moving average of $7.03. The firm has a market cap of $3.63 billion, a PE ratio of -6.07 and a beta of 0.86. Recursion Pharmaceuticals has a 1 year low of $5.60 and a 1 year high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RXRX shares. KeyCorp dropped their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.